Anti-Monkey/Human CD20 Antibody (2H7)
Anti-Monkey/Human CD20 Antibody (2H7) is a mouse-derived IgG2b κ type antibody inhibitor, targeting to monkey/human CD20. Anti-Monkey/Human CD20 Antibody (2H7) specifically depletes B cells. Anti-Monkey/Human CD20 Antibody (2H7) can be used for the researches of inflammation and metabolic disease, such as diabetes and experimental autoimmune encephalomyelitis.
For research use only. We do not sell to patients.
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Mouse IgG2b kappa
Monkey/Human
CD20
The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Anti-Monkey/Human CD20 Antibody (2H7) (200 μg, i.p., weekly) prevents or reverses myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis (EAE) in hCD20 transgenic C57BL/6 mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Spontaneous diabetes mice models (hCD20-transgenic NOD mice)[1]
-
Dosage:0.5 mg antibody in the first injection and 0.25 mg for the subsequent 3 injections
-
Administration:Intravenously injection, 9-day period with 4 injections at 3-day intervals
-
Result:Significantly delayed the progression of diabetes.
Showed significantly less infiltration of pancreatic islets.
-
Animal Model:MOG-induced experimental autoimmune encephalomyelitis (EAE) mice models (hCD20 transgenic C57BL/6 mice)[2]
-
Dosage:200 μg
-
Administration:Intraperitoneally injection, weekly
-
Result:Depleted 60% of B cells within established CNS lesions.
Suppressed development of proinflammatory T cells and clinical EAE.
P11836-1
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
in vivo B cell depletion in hCD20 Tg mice; Immunohistochemistry (frozen); Immunoprecipitation; Fl
Chemical Information
-
Molecular Weight 150 kDa
-
SMILES
[Anti-Monkey/Human CD20 Antibody (2H7)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Hu CY, et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest. 2007 Dec;117(12):3857-67. [Content Brief]
[2]. Weber MS, et al. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol. 2010 Sep;68(3):369-83. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Monkey/Human CD20 Antibody (2H7) Related Classifications
HY-P990138 Related Classifications
Powered by Bioz